Hetero Drugs Ltd.’s launch in India of its biosimilar rituximab, marketed as Maball, follows the other biosimilar versions of the cancer drug already launched by Dr. Reddy's Laboratories Ltd. (marketed as Reditux) and Intas Pharmaceuticals Ltd. (Mabtas), launched in 2007 and 2013 respectively.
Roche, though, has apparently not been actively promoting its original MabThera brand in India. Instead Roche's rituximab products are branded as Ristova and a second brand Ikgdar (through an alliance with the Indian firm Emcure Pharmaceuticals Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?